Advancing the Future of Epilepsy Care Through Research, Precision Medicine & Emerging Therapies

At Georgia Epilepsy & Neurology Institute, we believe that exceptional epilepsy care requires more than managing seizures — it requires advancing the science that shapes tomorrow’s treatments. Our physicians, Dr. Ki Hyeong Lee and Dr. Joo Hee Seo, bring deep experience in clinical research, advanced therapeutics, and precision‑based approaches to epilepsy management.

We are committed to connecting patients with innovative therapies, including gene‑targeted treatments, novel antiseizure medications, and research‑driven care pathways that are transforming outcomes for children and adults with epilepsy.

Our Commitment to Innovation

Epilepsy is a rapidly evolving field. New therapies, genetic discoveries, and device‑based treatments are emerging every year. Our practice stays at the forefront by:

  • Participating in clinical trials and research collaborations
  • Referring eligible patients to specialized gene‑therapy and precision‑medicine studies
  • Maintaining partnerships with Emory Epilepsy Center and Children’s Healthcare of Atlanta (CHOA)
  • Integrating the latest evidence into personalized treatment plans
  • Offering advanced diagnostics that support research‑level accuracy

Innovation is not an add‑on — it is built into the core of our practice.

Gene‑Targeted & Precision Therapies

Many epilepsies have a genetic basis. Understanding the underlying mutation can open the door to targeted treatments.

We evaluate and coordinate access to emerging therapies for conditions such as:

  • Dravet syndrome (SCN1A)
  • CDKL5 deficiency disorder
  • SCN2A, SCN8A, KCNQ2, KCNT1 epilepsies
  • Tuberous sclerosis complex (TSC1/TSC2)
  • Other developmental and epileptic encephalopathies (DEEs)

Our team guides families through:

  • Genetic testing pathways
  • Interpretation of results
  • Eligibility for gene‑targeted clinical trials
  • Long‑term precision‑based treatment planning

Novel Antiseizure Medications (ASMs)

We stay current with the newest FDA‑approved and investigational antiseizure medications, including:

  • Next‑generation sodium channel modulators
  • GABA‑modulating therapies
  • Cannabinoid‑based treatments
  • Therapies targeting specific genetic pathways

Patients with refractory epilepsy may qualify for trials evaluating:

  • New ASMs
  • Combination therapies
  • Age‑specific dosing strategies
  • Treatments for rare epileptic syndromes

We help determine eligibility and coordinate enrollment when appropriate.

Advanced Neuromodulation & Surgical Innovation

For patients with drug‑resistant epilepsy, we evaluate candidacy for:

  • Vagus Nerve Stimulation (VNS)
  • Responsive Neurostimulation (RNS)
  • Deep Brain Stimulation (DBS)
  • Laser ablation and resective surgery

Through our partnerships with Emory and CHOA, patients gain access to:

  • Advanced imaging
  • Intracranial EEG monitoring
  • Surgical trials and device‑based research
  • Post‑surgical long‑term outcome programs

We ensure every patient receives the right level of care at the right time.

Current & Upcoming Clinical Trials

We participate in and refer to trials involving:

  • Gene‑targeted therapies
  • Novel antiseizure medications
  • Precision‑medicine approaches
  • Pediatric and adult refractory epilepsy
  • Rare genetic epilepsies
  • Neuromodulation and device‑based therapies

Because trial availability changes frequently, our team provides up‑to‑date guidance during your visit.

Collaboration With Leading Epilepsy Centers

Our research‑driven care model is strengthened by close collaboration with:

  • Emory Epilepsy Center
  • Children’s Healthcare of Atlanta (CHOA)
  • National and international research networks
  • Industry‑sponsored clinical trial groups

These partnerships ensure our patients have access to the full spectrum of innovative therapies, from community‑based management to tertiary‑level research programs.

Who May Benefit From Clinical Trials?

Clinical trials may be appropriate for:

  • Patients with refractory epilepsy
  • Children with genetic epilepsies
  • Adults with drug‑resistant focal epilepsy
  • Patients who have exhausted standard treatment options
  • Families seeking access to emerging therapies
  • Individuals interested in contributing to scientific advancement

Our team evaluates eligibility and provides guidance tailored to each patient’s needs.

Our Philosophy: Innovation With Compassion

Research is most meaningful when it improves lives. We ensure that every patient considering a clinical trial receives:

  • Clear explanations
  • Honest expectations
  • Supportive guidance
  • Coordination with research teams
  • Long‑term follow‑up

Innovation is not just about new treatments — it’s about giving families hope, clarity, and access to the best care available.